The Role of Oxidized Phospholipids in Atherosclerosis

Overview

Journal J Lipid Res

Publisher Elsevier

Specialty Biochemistry

Date 2008 Dec 9

PMID 19059906

Citations 97

Authors

Judith A Berliner

Norbert Leitinger

Sotirios Tsimikas

Affiliations

Soon will be listed here.

Abstract

There is increasing evidence that oxidized phospholipids (OxPLs) play an important role in atherosclerosis. These phospholipids accumulate in human and mouse lesions. Specific OxPLs have been identified as major regulators of many cell types present in the vessel wall. In endothelial cells, >1,000 genes are regulated. Some of these genes are pro-atherogenic and others anti-atherogenic. The anti-atherogenic effects are likely important in slowing the atherogenic process. Several receptors and signaling pathways associated with OxPL action have been identified and shown to be upregulated in human lesions. A structural model of the mechanism by which specific OxPLs serve as CD36 ligands has been identified. Specific oxidized phospholipids are also present in plasma and associated with Lp(a) particles. In humans, OxPL/apolipoprotein B has been shown to be a prognostic indicator and a separate risk factor for coronary events. Levels of OxPL in plasma have been shown to be correlated with platelet activation. The results of these studies suggest an important role for OxPL in all stages of atherosclerosis.

Citing Articles

Lipoprotein(a) and Atrial Fibrillation: Mechanistic Insights and Therapeutic Approaches.

Zhang Z, Peng B, Nuranmubieke A, Xu Y, Liu Y, Tu T Int J Med Sci. 2025; 22(2):357-370.

PMID: 39781530 PMC: 11704704. DOI: 10.7150/ijms.102301.

Single chain fragment variable, a new theranostic approach for cardiovascular diseases.

Zahid R, Wang J, Cai Z, Ishtiaq A, Liu M, Ma D Front Immunol. 2024; 15:1443290.

PMID: 39735545 PMC: 11671482. DOI: 10.3389/fimmu.2024.1443290.

Selective regulation of macrophage lipid metabolism via nanomaterials' surface chemistry.

Wu J, Bai X, Yan L, Baimanov D, Cong Y, Quan P Nat Commun. 2024; 15(1):8349.

PMID: 39333092 PMC: 11436645. DOI: 10.1038/s41467-024-52609-7.

Lipoprotein(a) and cardiovascular disease.

Boffa M, Koschinsky M Biochem J. 2024; 481(19):1277-1296.

PMID: 39302109 PMC: 11555715. DOI: 10.1042/BCJ20240037.

The minimal membrane requirements for BAX-induced pore opening upon exposure to oxidative stress.

Mystek P, Singh V, Horvath M, Honzejkova K, Riegerova P, Evci H Biophys J. 2024; 123(20):3519-3532.

PMID: 39188056 PMC: 11494524. DOI: 10.1016/j.bpj.2024.08.017.

References

Imai Y, Kuba K, Neely G, Yaghubian-Malhami R, Perkmann T, van Loo G . Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008; 133(2):235-49. PMC: 7112336. DOI: 10.1016/j.cell.2008.02.043. View

Lee S, Li R, Kim B, Palvolgyi R, Ho T, Yang Q . Ox-PAPC activation of PMET system increases expression of heme oxygenase-1 in human aortic endothelial cell. J Lipid Res. 2008; 50(2):265-74. PMC: 2636922. DOI: 10.1194/jlr.M800317-JLR200. View

Chou M, Hartvigsen K, Hansen L, Fogelstrand L, Shaw P, Boullier A . Oxidation-specific epitopes are important targets of innate immunity. J Intern Med. 2008; 263(5):479-88. DOI: 10.1111/j.1365-2796.2008.01968.x. View

Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F . Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007; 27(8):1788-95. DOI: 10.1161/ATVBAHA.107.145805. View

Erridge C, Webb D, Spickett C . Toll-like receptor 4 signalling is neither sufficient nor required for oxidised phospholipid mediated induction of interleukin-8 expression. Atherosclerosis. 2006; 193(1):77-85. DOI: 10.1016/j.atherosclerosis.2006.08.032. View

Bochkov V, Kadl A, Huber J, Gruber F, Binder B, Leitinger N . Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature. 2002; 419(6902):77-81. DOI: 10.1038/nature01023. View

Miller Y, Viriyakosol S, Binder C, Feramisco J, Kirkland T, Witztum J . Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem. 2002; 278(3):1561-8. DOI: 10.1074/jbc.M209634200. View

Groeneweg M, Vergouwe M, Scheffer P, Vermue H, Sollewijn Gelpke M, Sijbers A . Modification of LDL with oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (oxPAPC) results in a novel form of minimally modified LDL that modulates gene expression in macrophages. Biochim Biophys Acta. 2008; 1781(6-7):336-43. DOI: 10.1016/j.bbalip.2008.04.016. View

Podrez E, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M . A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem. 2002; 277(41):38517-23. DOI: 10.1074/jbc.M205924200. View

10.

Anuurad E, Boffa M, Koschinsky M, Berglund L . Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med. 2006; 26(4):751-72. DOI: 10.1016/j.cll.2006.07.002. View

11.

Walton K, Cole A, Yeh M, Subbanagounder G, Krutzik S, Modlin R . Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2. Arterioscler Thromb Vasc Biol. 2003; 23(7):1197-203. DOI: 10.1161/01.ATV.0000079340.80744.B8. View

12.

Chen R, Yang L, McIntyre T . Cytotoxic phospholipid oxidation products. Cell death from mitochondrial damage and the intrinsic caspase cascade. J Biol Chem. 2007; 282(34):24842-50. PMC: 2701377. DOI: 10.1074/jbc.M702865200. View

13.

Cruz D, Watson A, Miller C, Montoya D, Ochoa M, Sieling P . Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest. 2008; 118(8):2917-28. PMC: 2467381. DOI: 10.1172/JCI34189. View

14.

Friedman P, Horkko S, Steinberg D, Witztum J, Dennis E . Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J Biol Chem. 2001; 277(9):7010-20. DOI: 10.1074/jbc.M108860200. View

15.

Shamshiev A, Ampenberger F, Ernst B, Rohrer L, Marsland B, Kopf M . Dyslipidemia inhibits Toll-like receptor-induced activation of CD8alpha-negative dendritic cells and protective Th1 type immunity. J Exp Med. 2007; 204(2):441-52. PMC: 2118729. DOI: 10.1084/jem.20061737. View

16.

Gugiu B, Mouillesseaux K, Duong V, Herzog T, Hekimian A, Koroniak L . Protein targets of oxidized phospholipids in endothelial cells. J Lipid Res. 2007; 49(3):510-20. DOI: 10.1194/jlr.M700264-JLR200. View

17.

Tsimikas S . In vivo markers of oxidative stress and therapeutic interventions. Am J Cardiol. 2008; 101(10A):34D-42D. DOI: 10.1016/j.amjcard.2008.02.006. View

18.

Seyerl M, Bluml S, Kirchberger S, Bochkov V, Oskolkova O, Majdic O . Oxidized phospholipids induce anergy in human peripheral blood T cells. Eur J Immunol. 2008; 38(3):778-87. DOI: 10.1002/eji.200737619. View

19.

Gargalovic P, Imura M, Zhang B, Gharavi N, Clark M, Pagnon J . Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc Natl Acad Sci U S A. 2006; 103(34):12741-6. PMC: 1568918. DOI: 10.1073/pnas.0605457103. View

20.

Bergmark C, Dewan A, Orsoni A, Merki E, Miller E, Shin M . A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008; 49(10):2230-9. DOI: 10.1194/jlr.M800174-JLR200. View